Vol 4, No 4 (2024)

decorative image of the issue cover

Viewpoint

Viewpoint: Model Validation Tool

Karen M. Lee

Published April 16, 2024

PDF HTML

Reimbursement Recommendations

Nirmatrelvir-Ritonavir (Paxlovid)

CADTH

Published April 30, 2024

PDF HTML

Teclistamab (Tecvayli)

CADTH

Published April 24, 2024

PDF HTML

Drospirenone (Slynd)

CADTH

Published April 4, 2024

PDF HTML

Inebilizumab (Uplizna)

CADTH

Published April 2, 2024

PDF HTML

Ravulizumab (Ultomiris)

CADTH

Published April 2, 2024

PDF HTML

Reimbursement Reviews

Belumosudil (Rezurock)

CADTH

Published April 30, 2024

PDF HTML

Vutrisiran (Amvuttra)

CADTH

Published April 29, 2024

PDF HTML

Niraparib and Abiraterone Acetate (Akeega)

CADTH

Published April 29, 2024

PDF HTML

Olaparib (Lynparza)

CADTH

Published April 25, 2024

PDF HTML

Sacituzumab Govitecan (Trodelvy)

CADTH

Published April 24, 2024

PDF HTML

Glofitamab (Columvi)

CADTH

Published April 23, 2024

PDF HTML

Evinacumab (Evkeeza)

CADTH

Published April 17, 2024

PDF HTML

Efgartigimod Alfa (Vyvgart)

CADTH

Published April 4, 2024

PDF HTML

Ibrutinib (Imbruvica)

CADTH

Published April 2, 2024

PDF HTML

Calaspargase Pegol (Asparlas)

CADTH

Published April 2, 2024

PDF HTML

Health Technology Reviews

Renal Denervation for Uncontrolled Hypertension

CADTH

Published April 8, 2024

PDF HTML

View All Issues